文献速递糖尿病肥胖与代谢综合征

糖尿病预防计划及其结局研究:NIDDK 对 2 型糖尿病预防的探索及其公共卫生影响

The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact.
PubMed 文献 · Diabetes Care · 2025-01-01

本文回顾美国国立糖尿病、消化和肾脏疾病研究所(NIDDK)于1996年发起的多中心随机临床试验糖尿病预防计划(DPP)及其后续结局研究(DPPOS)。DPP 中强化生活方式干预(ILS)使糖尿病风险降低58%、二甲双胍降低31%;DPPOS 中位总随访超过21年,与原安慰剂组相比,原 ILS 组和二甲双胍组糖尿病累积发病率分别降低24%和17%。

要点

  • DPP 为多中心随机临床试验,纳入糖尿病前期高危人群,对比 ILS、二甲双胍与安慰剂。
  • 平均2.8年后 ILS 使糖尿病风险降低58%、二甲双胍降低31%,研究因两种干预均显示有效而提前终止。
  • DPPOS 中位总随访超过21年,原 ILS 组和二甲双胍组糖尿病累积发病率较安慰剂组分别降低24%和17%。

核心结论

  • 在高危糖尿病前期人群中,ILS 和二甲双胍均可降低糖尿病的发生风险,长期随访中原 ILS 组和二甲双胍组糖尿病累积发病率仍低于原安慰剂组。
  • 长期随访期间,原 DPP 干预对微血管或心血管结局无显著影响;但与进展为糖尿病的参与者相比,未进展者的微血管结局患病率显著更低。

研究设计与样本

  • NIDDK 于1996年发起多中心随机临床试验 DPP,由研究者与 NIDDK 工作人员共同设计,主要目标为确定 ILS 或二甲双胍对比安慰剂能否减少糖尿病前期高危人群的糖尿病发生。
  • 2002年启动 DPP 的延伸研究 DPPOS,用于考察糖尿病预防的长期病程与后果。

主要发现

  • 平均2.8年后,ILS 使糖尿病风险降低58%,二甲双胍降低31%,两种干预均显示有效,研究提前终止。
  • DPPOS 中位总随访超过21年,与原安慰剂组相比,原 ILS 组和原二甲双胍组糖尿病累积发病率分别降低24%和17%。
  • 原 ILS 组和原二甲双胍组每人无糖尿病生存期中位延长分别为3.5年和2.5年。
  • 长期随访期间,原 DPP 干预对微血管或心血管结局无显著影响。
  • 与进展为糖尿病的参与者相比,未进展者的微血管结局患病率显著更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current-day epidemic of type 2 diabetes, largely driven by increased adiposity and reduced physical activity in the setting of genetic susceptibility, is a major public health challenge. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) presciently proposed the Diabetes Prevention Program (DPP), a multicenter randomized clinical trial, designed by investigators in conjunction with NIDDK staff and initiated in 1996. The primary goal of DPP was to determine whether an intensive lifestyle intervention (ILS) or metformin in comparison with placebo would reduce the development of diabetes in a high-risk population with prediabetes. After mean 2.8 years, ILS reduced diabetes risk by 58% and metformin by 31%, leading to study termination ahead of schedule due to demonstrated efficacy of both interventions. In 2002, an extension of the DPP study, the Diabetes Prevention Program Outcomes Study (DPPOS), was initiated for examination of the longer-term course and consequences of diabetes prevention. Over 21 years of median total follow-up, in comparison with the placebo group, cumulative diabetes incidence was reduced by 24% and 17% in the original ILS and metformin groups, respectively, with median increases in diabetes-free survival of 3.5 and 2.5 years/person. During long-term follow-up, there were no significant effects of the original DPP interventions on microvascular or cardiovascular outcomes. However, compared with prevalence of microvascular outcomes among participants who progressed to diabetes, prevalence among those who did not progress was significantly lower. Longer-term follow-up of the cohort continues with examination of relationships between diabetes and prediabetes and an expanded array of diabetes- and aging-related morbidities.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Crandall JP, Dabelea D, Knowler WC, et al. The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact. Diabetes Care. 2025. PMID: 40272279. doi:10.2337/dc25-0014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。